Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Bivision logo — Pioneering biomedical advancements in targeted radiopharmace...

Bivision

Pioneering biomedical advancements in targeted radiopharmaceuticals for integrated visual diagnosis and treatment.

Founded 2021 Angel Total: $100.00M Biopharma, Biotechnology +1

General Information

Company Name Bivision
Founded Year 2021
Industries Biopharma, Biotechnology, Health Care
Funding Stage Angel
Social

BounceWatch is an independent company data service, not affiliated with Bivision. To contact Bivision, visit bivisionpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Bivision

Biovion is a biomedical startup founded in 2021 with a focus on pioneering advancements in targeted radiopharmaceuticals (TRT) for integrated visual diagnosis and treatment. This innovative venture operates within the Biopharma, Biotechnology, and Health Care industries. Their latest milestone includes securing a notable CNY100.00M Angel Round investment on 10 August 2022 from renowned investors such as Gaorong Capital, Kaitai Capital, Viventures, and Lichen Capital. The company's slogan underlines its commitment to pushing the boundaries of biomedicine and signifies its potential to make a significant impact in the healthcare sector.

Taxonomy: biomedical advancements, targeted radiopharmaceuticals, visual diagnosis, treatment, biomedical enterprise, TRT, biomedical, radiopharmaceuticals, medical imaging

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Angel Round CNY100.00M 4
Gaorong Capital Kaitai Capital Viventures
Gaorong Capital, Kaitai Capital +2
10 Aug 2022
Seed Round Undisclosed 2
Kaitai Capital Yijing Capital
Kaitai Capital, Yijing Capital
01 Jan 2022

Bivision Alternatives & Competitors

View All Alternatives
Bivision vs
Clarity Pharmaceuticals
Clarity Pharmaceuticals Australia

Clarity is developing next-generation products to address the growing need for radiopharmaceuticals...

Venture round
61 employees
Biotechnology, Health Care
Bivision vs
Resproly
Resproly

Pioneering advanced respiratory solutions for Asthma, COPD, Diabetes, and Parkinson's Disease.

Series B
Biopharma, Biotechnology
Bivision vs
Telormedix
Telormedix

Pioneering targeted immunity for cancer and autoimmune disease treatment through innovative biopharm...

Series B
Biopharma, Biotechnology
View all alternatives

FAQ About Bivision

Pioneering biomedical advancements in targeted radiopharmaceuticals for integrated visual diagnosis and treatment.
Bivision was founded in 2021.
Bivision operates in Biopharma, Biotechnology and Health Care. Its work centres on biomedical advancements, targeted radiopharmaceuticals, visual diagnosis and treatment.
Bivision has completed 2 funding rounds, raising a total of $100.00M. The latest funding stage is Angel.
Top alternatives and competitors to Bivision include Clarity Pharmaceuticals, Resproly, Telormedix, Chase Pharmaceuticals, Alivio Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bivision and Clarity Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bivision, https://bouncewatch.com/company/bivision, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes